NetScientific (NSCI), the investment and commercialisation group with an
international portfolio of innovative life science, sustainability and technology
companies, reported yesterday (27.02.2023) that its portfolio company, PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy
company, the successful completion of a Type B meeting with the US Food and
Drug Administration (FDA). The meeting clears the way to start a pivotal study of
a combination therapy of PDS ....
28 Feb 2023
NetScientific (NSCI) – Corporate – PDS Biotech completes successful meeting with FDA for combination treatment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
NetScientific (NSCI) – Corporate – PDS Biotech completes successful meeting with FDA for combination treatment
NetScientific plc (NSCI:LON) | 63.0 0 0.0% | Mkt Cap: 15.1m
- Published:
28 Feb 2023 -
Author:
Matthew Davis | Emma Ulker -
Pages:
4
NetScientific (NSCI), the investment and commercialisation group with an
international portfolio of innovative life science, sustainability and technology
companies, reported yesterday (27.02.2023) that its portfolio company, PDS
Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy
company, the successful completion of a Type B meeting with the US Food and
Drug Administration (FDA). The meeting clears the way to start a pivotal study of
a combination therapy of PDS ....